Navigation Links
Hard To Treat Diseases (HTDS.PK) Completes India Order
Date:7/10/2009

SHENZHEN, China, July 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com - announced today that the second batch of Hepatitis A Vaccine of 2009 was delivered to India, by the company.

This is the second completed batch exported to India this year by the company. The first batch was delivered to India in March.

In summary, many people are recommended to receive Hepatitis A vaccine, including people at increased risk for exposure to HAV infection and people who are more likely to get seriously ill if infected with HAV. According to CDC recommendations, people who should be vaccinated include:

    -   All children at age 1 year (12-23 months)
    -   People age 12 months or older who are traveling to or working in an
        area of the world except the United States, Canada, Western Europe,
        Japan, New Zealand, and Australia
    -   Men who have sex with men
    -   Users of illegal drugs, both oral and injecting
    -   People who have blood clotting disorders
    -   People who work with HAV-infected primates or with HAV in a research
        laboratory setting (no other groups have been shown to be at
        increased risk for HAV infection because of occupational exposure)
    -   People with chronic liver disease
    -   Any person who wishes to be immune to Hepatitis A

More about of Hepatitis A Vaccine can be found on this World Health Organization link http://www.who.int/vaccines/en/hepatitisa.shtml

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hard To Treat Diseases (HTDS.PK) Reasserting Multi Million Dollar IP Ownership Rights
2. Anti-angiogenesis treatment improves hearing in some NF2 patients
3. Drug Shows Promise in Nervous-System Tumor Treatment
4. Advanced Heart Procedure Treats Growing Problem
5. 'Comparative Effectiveness' Research Addresses Options for Treating Prostate Cancer
6. Evidence-based information about complementary and alternative medicine treatments now available
7. Researchers identify potential patient safety risks among methadone maintenance treatment patients
8. Global Fund Increases AIDS, Tuberculosis and Malaria Prevention and Treatment Measures by 30-50% Over One Year
9. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
10. National Survey: Americans Fear Paying for Cancer Treatment As Much As Dying of the Disease
11. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... The Association of Healthcare and Value ... their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide the ... value analysis professionals have a ‘seat at the table’ with clinical committees when ...
(Date:3/27/2017)... ... March 27, 2017 , ... Sodium determination is consistently becoming ... require expert user knowledge. In a live webinar on April 11th and October ... highly accurate, determination of sodium. , It has long been known that too ...
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... ... overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the ... McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription ...
(Date:3/25/2017)... ... ... Getting earned media coverage meaningful for Garden Media Group's clients is the ... Garden Media aims to provide material helpful to clients’ goals and bottom lines. By ... messages to gain coveted media placements, Garden Media wows clients year-round. , Here ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... will spark a conversation on the current obstacles facing infection prevention and offer ... preventable deaths caused by these infections. , The print component of “Fighting ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
(Date:3/24/2017)... Research and Markets has announced the ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report ... cell therapy manufacturing and focuses both on contract manufacturers and ... anticipated to emerge as viable alternatives to conventional treatment options. ...
(Date:3/24/2017)... , March 24, 2017  Zymo ... company, and Hamilton Robotics, Inc., who designs, ... an ongoing collaboration that teams Zymo Research,s ... RNA and DNA extraction products with Hamilton,s ... created optimized methods for microbiomics and RNA ...
Breaking Medicine Technology: